{"id":"W2083901189","doi":"10.12703/p6-93","title":"Expanding use of new oral anticoagulants","year":2014,"lang":"en","type":"review","venue":"F1000Prime Reports","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute","funders":"Heart and Stroke Foundation of Canada","keywords":"Rivaroxaban; Apixaban; Dabigatran; Edoxaban; Medicine; Warfarin; Direct thrombin inhibitor; Atrial fibrillation; Vitamin K antagonist; Intensive care medicine; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000426571,0.0003566822,0.003168803,0.0004249662,0.00003369626,0.00003560776,0.00006576376,0.0002736466,0.0002989475],"category_scores_gemma":[0.0006080116,0.0002669811,0.0009170217,0.0003710654,0.00003378449,0.00009955,0.0001174831,0.0001645964,0.00007049181],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007101696,"about_ca_system_score_gemma":0.0003322831,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001040886,"about_ca_topic_score_gemma":0.000001219396,"domain_scores_codex":[0.9973565,0.00006848072,0.00143714,0.0004197086,0.0004650874,0.0002530999],"domain_scores_gemma":[0.9974028,0.0001741813,0.00136877,0.000798446,0.00006664074,0.000189105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001298193,0.000007905541,0.01436486,0.01203934,0.0005657565,0.0004359755,0.00001528278,9.164274e-7,0.000003254253,0.00006406286,0.01050066,0.961989],"study_design_scores_gemma":[0.0001757875,0.00004593818,0.0009603368,0.008201642,0.002682889,0.0004485984,0.000001415158,0.000001728249,0.00001370596,0.00002310366,0.9872154,0.0002294294],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001825537,0.9955844,0.0003445212,0.0000331663,0.000925041,0.001166988,0.000002882713,0.0001122608,0.001648221],"genre_scores_gemma":[0.0001766441,0.9709055,0.001598175,0.00002367542,0.001132564,0.000001672796,0.0002013067,0.00007334664,0.0258871],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9767148,"threshold_uncertainty_score":0.9999782,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3105205717858217,"score_gpt":0.4524429180358406,"score_spread":0.141922346250019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}